These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 15482692

  • 21. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon?
    Cottoni F, Bolognini S, Deplano A, Garrucciu G, Manzoni NE, Careddu GF, Montesu MA, Tocco A, Lissia A, Solinas A.
    Acta Derm Venereol; 2004; 84(2):120-3. PubMed ID: 15206691
    [Abstract] [Full Text] [Related]

  • 22. Severe streptococcal cellulitis after subcutaneous pegylated interferon alfa-2B in a diabetic patient.
    Lanternier F, Bon C, Memain N, Roulot D, Lortholary O.
    Gastroenterol Clin Biol; 2004 Dec; 28(12):1294-5. PubMed ID: 15671943
    [No Abstract] [Full Text] [Related]

  • 23. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Vinagre I, Rigla M, Torras X, Enríquez J, Corcoy R.
    Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Ann Intern Med; 2013 Dec 03; 159(11):729-38. PubMed ID: 24297189
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cutaneous reactions to interferon and ribavirin.
    Chamberlain AJ, Poon E.
    Intern Med J; 2004 Aug 03; 34(8):519. PubMed ID: 15317557
    [No Abstract] [Full Text] [Related]

  • 29. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Martínez-Bauer E, Forns X.
    Gastroenterol Hepatol; 2003 May 03; 26(5):303-6. PubMed ID: 12732104
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC, Chien RN.
    Aliment Pharmacol Ther; 2013 Feb 03; 37(4):492. PubMed ID: 23336679
    [No Abstract] [Full Text] [Related]

  • 34. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
    Tavakoli-Tabasi S, Bagree A.
    J Clin Gastroenterol; 2012 Feb 03; 46(2):162-7. PubMed ID: 21814144
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS, Chu PL, Liu CH, Chung GB, Wu KD.
    J Clin Gastroenterol; 2008 Jan 03; 42(1):112-3. PubMed ID: 18097301
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.